Constellation Pharmaceuticals Inc (CNST) Stock Price, Quote, News and Overview
NASDAQ:CNST - Nasdaq -
CNST Quote, Performance and Key Statistics
33.99
+0.02 (+0.06%)
The current stock price of CNST is 33.99 null. In the past month the price increased by 0.77%. In the past year, price increased by 16.8%.
CNST Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CNST
Company Profile
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company is headquartered in Cambridge, Massachusetts and currently employs 154 full-time employees. The company went IPO on 2018-07-19. The firm has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The firm is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.
Company Info
Constellation Pharmaceuticals Inc
215 1st St Ste 200
Cambridge MASSACHUSETTS 02142 US
CEO: Jigar Raythatha
Employees: 154.0
Company Website: https://www.constellationpharma.com/
Phone: 16177140555.0
Constellation Pharmaceuticals Inc / CNST FAQ
What is the stock price of Constellation Pharmaceuticals Inc today?
The current stock price of CNST is 33.99 null. The price increased by 0.06% in the last trading session.
What is the ticker symbol for Constellation Pharmaceuticals Inc stock?
The exchange symbol of Constellation Pharmaceuticals Inc is CNST and it is listed on the Nasdaq exchange.
On which exchange is CNST stock listed?
CNST stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Constellation Pharmaceuticals Inc stock?
7 analysts have analysed CNST and the average price target is 41.53 null. This implies a price increase of 22.18% is expected in the next year compared to the current price of 33.99. Check the Constellation Pharmaceuticals Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Constellation Pharmaceuticals Inc worth?
Constellation Pharmaceuticals Inc (CNST) has a market capitalization of 1.63B null. This makes CNST a Small Cap stock.
How many employees does Constellation Pharmaceuticals Inc have?
Constellation Pharmaceuticals Inc (CNST) currently has 154.0 employees.
What are the support and resistance levels for Constellation Pharmaceuticals Inc (CNST) stock?
Constellation Pharmaceuticals Inc (CNST) has a support level at 33.94 and a resistance level at 36.85. Check the full technical report for a detailed analysis of CNST support and resistance levels.
Should I buy Constellation Pharmaceuticals Inc (CNST) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNST, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNST, evaluating the profitability, health, valuation and growth aspects
- Constellation Pharmaceuticals Inc (CNST) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Constellation Pharmaceuticals Inc (CNST) Sales and EPS estimates to see what analysts future expectations are.
- Constellation Pharmaceuticals Inc (CNST) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Constellation Pharmaceuticals Inc (CNST) Insider and Institutional Ownership to learn about the owners and their transactions.
- Constellation Pharmaceuticals Inc (CNST) Stock Chart to make your own analysis
- Constellation Pharmaceuticals Inc (CNST) Latest news and press-releases to stay up to date.
Does Constellation Pharmaceuticals Inc (CNST) stock pay dividends?
CNST does not pay a dividend.
When does Constellation Pharmaceuticals Inc (CNST) report earnings?
Constellation Pharmaceuticals Inc (CNST) will report earnings on 2022-03-04, before the market open.
What is the Price/Earnings (PE) ratio of Constellation Pharmaceuticals Inc (CNST)?
Constellation Pharmaceuticals Inc (CNST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.04).
CNST Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CNST. When comparing the yearly performance of all stocks, CNST is one of the better performing stocks in the market, outperforming 78.24% of all stocks.
CNST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNST. CNST has a great financial health rating, but its profitability evaluates not so good.
CNST Financial Highlights
Over the last trailing twelve months CNST reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS decreased by -4.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.01% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CNST Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 71% to CNST. The Buy consensus is the average rating of analysts ratings from 7 analysts.